Endometrial giant cell carcinoma: a case report and review of the literature

Background: Endometrial giant cell carcinoma (EGCC) is a rare form of endometrial carcinoma (EC) with limited documentation in medical literature, consisting of only two small series and a few case reports. Till now, the World Health Organization (WHO) classification of endometrial neoplasms does not recognize EGCC as a distinct entity. Due to its rarity, there is a lack of comprehensive data on the biological characteristics, clinical management and prognosis of EGCC. Cases: In this report, we present a rare case of EGCC in a 55-year-old postmenopausal woman, describe its clinicopathologic features and review the relevant literature. The patient underwent a comprehensive surgical procedure, including a total abdominal hysterectomy, bilateral salpingo-oophorectomy and pelvic lymphadenectomy. Postoperative radiochemotherapy was not administered, and no evidence of disease recurrence was observed during the one-year follow-up period. Conclusions: Although there is insufficient evidence to definitively classify EGCC as a distinct uterine malignancy, our review of the relevant literature suggests that it may exhibit aggressive behavior based on its clinicopathological and molecular characteristics, and the presence and/or percentage of giant cell components should be clearly mentioned in pathological reports to highlight uncertainty regarding its biological characteristics. Further accumulation of experiences is necessary to improve the diagnosis and treatment of this uncommon tumor.

Giant cell carcinoma; Endometrial carcinoma; Carcinosarcoma; p53; Case report

[1] WHO Classification of Tumours Editorial Board. Female Genital Tumours. 5th edn. IARC (International Agency for Research on Cancer): Geneva. 2020.

[2] Jones MA, Young RH, Scully RE. Endometrial adenocarcinoma with a component of giant cell carcinoma. International Journal of Gynecological Pathology. 1991; 10: 260–270.

[3] Mardi K, Sharma M. Giant cell carcinoma of the endometrium. Internet Scientific Publications. 2008; 12: 1–3.

[4] Mulligan AM, Plotkin A, Rouzbahman M, Soslow RA, Gilks CB, Clarke BA. Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells. The American Journal of Surgical Pathology. 2010; 34: 1132–1138.

[5] Bhattacharyya A, Gon S, Bandyopadhyay G, Majumdar B, Gayen P. Giant cell carcinoma of endometrium: a rare clinical entity. Iranian Journal of Pathology. 2012; 7: 197–202.

[6] Sharma P, Ahluwalia C, Kolte S, Mandal AK. Giant cell carcinoma of endometrium: a rare case report and review of literature. Clinical Cancer Investigation Journal. 2016; 5: 79–82.

[7] Ayık Aydın H, Tuncer HA, Erdoğan G, Şimşek T. Uterine giant cell carcinoma: a case report and review of the literature. Turkish Journal of Obstetrics and Gynecology 2019; 16: 76–79.

[8] Arafah M, Bokhari RA, Akkour K, Raddaoui E. Giant cell carcinoma of the endometrium: a case report of a rare entity with aggressive behavior. American Journal of Case Reports. 2021; 22: e932916.

[9] Arciuolo D, Travaglino A, Raffone A, Santoro A, Russo G, Minucci A, et al. Endometrial giant cell carcinoma: new insights from a morphological, immunohistochemical, and molecular analysis of three cases. Virchows Archiv. 2022; 481: 321–326.

[10] Kang EY, Tessier-Cloutier B, Duggan MA, Stewart CJR, Lee CH, Köbel M. Loss of ARID1B and SMARCB1 expression are specific for the diagnosis of dedifferentiated/undifferentiated carcinoma in tumours of the upper gynaecological tract and cervix. Histopathology. 2021; 79: 160–167.

[11] Santoro A, Angelico G, Travaglino A, Inzani F, Arciuolo D, Valente M, et al. New pathological and clinical insights in endometrial cancer in view of the updated ESGO/ESTRO/ESP guidelines. Cancers. 2021; 13: 2623.

[12] Travaglino A, Raffone A, Gencarelli A, Mollo A, Guida M, Insabato L, et al. TCGA classification of endometrial cancer: the place of carcinosarcoma. Pathology and Oncology Research. 2020; 26: 2067–2073.